Literature DB >> 28711140

Precision Medicine in Rheumatoid Arthritis.

James Bluett1, Anne Barton2.   

Abstract

Treatment of rheumatoid arthritis (RA) has substantially improved in recent years because of the development of novel drugs. However, response is not universal for any of the treatment options, and selection of an effective therapy is currently based on a trial-and-error approach. Delayed treatment response increases the risk of progressive joint damage and resultant disability and also has a significant impact on quality of life for patients. For many drugs, the patient's genetic background influences response to therapy, and understanding the genetics of response to therapy in RA may allow for targeted personalized health care.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anti-TNF; Anti-TNF response; Genetic; Genomic; Methotrexate; Pharmacogenomics; Rheumatoid arthritis

Mesh:

Substances:

Year:  2017        PMID: 28711140     DOI: 10.1016/j.rdc.2017.04.008

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN: 0889-857X            Impact factor:   2.670


  20 in total

1.  CUL4B promotes the pathology of adjuvant-induced arthritis in rats through the canonical Wnt signaling.

Authors:  Chenggui Miao; Jun Chang; Guoxue Zhang; Hao Yu; Lili Zhou; Guoliang Zhou; Chuanlei Zhao
Journal:  J Mol Med (Berl)       Date:  2018-04-06       Impact factor: 4.599

2.  Methotrexate disposition, anti-folate activity and efficacy in the collagen-induced arthritis mouse model.

Authors:  Rakesh K Singh; Leon van Haandel; Paul Kiptoo; Mara L Becker; Teruna J Siahaan; Ryan S Funk
Journal:  Eur J Pharmacol       Date:  2019-04-02       Impact factor: 4.432

Review 3.  Precision medicine journey through omics approach.

Authors:  Mandana Hasanzad; Negar Sarhangi; Sima Ehsani Chimeh; Nayereh Ayati; Monireh Afzali; Fatemeh Khatami; Shekoufeh Nikfar; Hamid Reza Aghaei Meybodi
Journal:  J Diabetes Metab Disord       Date:  2021-11-24

4.  Systems-biology analysis of rheumatoid arthritis fibroblast-like synoviocytes implicates cell line-specific transcription factor function.

Authors:  Richard I Ainsworth; Deepa Hammaker; Gyrid Nygaard; Cecilia Ansalone; Camilla Machado; Kai Zhang; Lina Zheng; Lucy Carrillo; Andre Wildberg; Amanda Kuhs; Mattias N D Svensson; David L Boyle; Gary S Firestein; Wei Wang
Journal:  Nat Commun       Date:  2022-10-20       Impact factor: 17.694

Review 5.  Subcutaneous abatacept in rheumatoid arthritis: A real-life experience.

Authors:  Juan Camilo Sarmiento-Monroy; Luisa Parada-Arias; Milena Rodríguez-López; Mónica Rodríguez-Jiménez; Nicolás Molano-González; Adriana Rojas-Villarraga; Rubén Darío Mantilla
Journal:  J Transl Autoimmun       Date:  2019-09-06

6.  Factors associated with drug survival on first biologic therapy in patients with rheumatoid arthritis: a population-based cohort study.

Authors:  Mohammad E Naffaa; Fadi Hassan; Avivit Golan-Cohen; Eugene Merzon; Ilan Green; Amir Saab; Ziv Paz
Journal:  Rheumatol Int       Date:  2021-09-16       Impact factor: 2.631

7.  A Novel Circulating miRNA-Based Model Predicts the Response to Tripterysium Glycosides Tablets: Moving Toward Model-Based Precision Medicine in Rheumatoid Arthritis.

Authors:  Yanqiong Zhang; Hailong Wang; Xia Mao; Qiuyan Guo; Weijie Li; Xiaoyue Wang; Guangyao Li; Quan Jiang; Na Lin
Journal:  Front Pharmacol       Date:  2018-05-24       Impact factor: 5.810

8.  Piggybacked by PEGylation?

Authors:  Kichul Shin
Journal:  Korean J Intern Med       Date:  2018-10-30       Impact factor: 2.884

9.  A Molecular Signature Response Classifier to Predict Inadequate Response to Tumor Necrosis Factor-α Inhibitors: The NETWORK-004 Prospective Observational Study.

Authors:  Stanley Cohen; Alvin F Wells; Jeffrey R Curtis; Rajat Dhar; Theodore Mellors; Lixia Zhang; Johanna B Withers; Alex Jones; Susan D Ghiassian; Mengran Wang; Erin Connolly-Strong; Sarah Rapisardo; Zoran Gatalica; Dimitrios A Pappas; Joel M Kremer; Alif Saleh; Viatcheslav R Akmaev
Journal:  Rheumatol Ther       Date:  2021-06-19

10.  Regulatory T cells as a biomarker for response to adalimumab in rheumatoid arthritis.

Authors:  Dao X Nguyen; Alice Cotton; Laura Attipoe; Coziana Ciurtin; Caroline J Doré; Michael R Ehrenstein
Journal:  J Allergy Clin Immunol       Date:  2018-06-20       Impact factor: 10.793

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.